CD8A and myeloid sarcoma: As it has been shown that Cbl is an immunomodulator that regulates the ratio of CD4+/CD8+ T cells and natural killer cell activity in humans [376,377,378], we should theoretically consider the possibility that Cbl deficiency in the MS SC may also play a role in determining the local immunological response.